Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Cancer"
DOI: 10.1002/cncr.32645
Abstract: Immune checkpoint inhibitors (ICIs) represent an appealing treatment for patients with advanced urothelial cancer (aUC) and a poor performance status (PS). However, the benefit of ICIs for patients with a poor PS remains unknown. It… read more here.
Keywords: immune checkpoint; performance status; urothelial cancer; checkpoint inhibitors ... See more keywords
Comparing survival in trial‐ versus routine‐care advanced urothelial cancer patients on immune checkpoint blockade
Sign Up to like & getrecommendations! Published in 2024 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.5798
Abstract: Although recent trials involving first‐line immune checkpoint inhibitors have expanded treatment options for patients with advanced urothelial carcinoma (aUC) who are ineligible for standard cisplatin‐based chemotherapy, there exists limited evidence for whether trial efficacy translates… read more here.
Keywords: advanced urothelial; immune checkpoint; trial; routine care ... See more keywords
Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-019-01613-9
Abstract: Background Prognostic outcomes and safety following treatment with pembrolizumab in patients with advanced urothelial carcinoma (UC) have not been fully elucidated in clinical practice. The aim of this study was to evaluate the oncological efficacy… read more here.
Keywords: prognostic outcomes; safety; outcomes safety; advanced urothelial ... See more keywords
PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2019.03.009
Abstract: Chemotherapy is no longer the only viable option for patients with locally advanced or metastatic urothelial carcinoma. Immunotherapy, as checkpoint inhibition, has received United States Food and Drug Administration approval in the preceding several years,… read more here.
Keywords: line; current clinical; combinations advanced; clinical trials ... See more keywords
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Nature medicine"
DOI: 10.1038/s41591-021-01317-6
Abstract: Durvalumab is a programmed death-ligand 1 (PD-L1) inhibitor with clinical activity in advanced urothelial cancer (AUC)1. AUC is characterized by several recurrent targetable genomic alterations2-5. This study ( NCT02546661 , BISCAY) combined durvalumab with relevant… read more here.
Keywords: urothelial cancer; biomarker; study; advanced urothelial ... See more keywords
Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitors
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-72755-8
Abstract: Real-world data on health-related quality of life (HRQoL) in advanced urothelial carcinoma (aUC) receiving immune checkpoint inhibitors (ICIs) are limited. This study included 42 patients with aUC who received second-line or later pembrolizumab (n = 19), maintenance… read more here.
Keywords: urothelial carcinoma; related quality; health related; quality life ... See more keywords
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx400
Abstract: Background Five-year survival of patients with inoperable, advanced urothelial carcinoma treated with the first-line chemotherapy is 5%-15%. We assessed whether the Hsp27 inhibitor apatorsen combined with gemcitabine plus cisplatin (GC) could improve overall survival (OS)… read more here.
Keywords: chemotherapy; first line; placebo controlled; apatorsen ... See more keywords
Remarkable response to gemcitabine rechallenge in advanced urothelial carcinoma: a case report
Sign Up to like & getrecommendations! Published in 2022 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001387
Abstract: Therapeutic alternatives in advanced urothelial carcinoma are limited, especially in advanced lines, with only a few drugs having demonstrated relevant clinical benefit. This article discusses about a young patient with significant cardiovascular comorbidities, already treated… read more here.
Keywords: advanced urothelial; gemcitabine rechallenge; urothelial carcinoma;
Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15233
Abstract: Patients with advanced urothelial carcinoma (UC) who progress after platinum‐based chemotherapy have a poor prognosis, and there is a medical need to improve current treatment options. Ramucirumab plus docetaxel significantly improved progression‐free survival but not… read more here.
Keywords: exposure response; trial; advanced urothelial; urothelial carcinoma ... See more keywords
First‐line checkpoint inhibitors in PD‐L1‐positive patients with advanced urothelial carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "BJU International"
DOI: 10.1111/bju.14627
Abstract: More than 50% of all patients with advanced urothelial carcinoma cannot receive highly toxic cisplatin-based chemotherapy as the first-line treatment because of their unsatisfactory performance status and co-morbidities. Replacement of cisplatin with carboplatin does not… read more here.
Keywords: patients advanced; first line; advanced urothelial; urothelial carcinoma ... See more keywords
Association of prior local therapy and outcomes with PD(L)1 inhibitor in advanced urothelial cancer.
Sign Up to like & getrecommendations! Published in 2021 at "BJU international"
DOI: 10.1111/bju.15603
Abstract: OBJECTIVES To compare clinical outcomes with anti-PD(L)1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation (RT) prior to developing metastatic disease.… read more here.
Keywords: line; treatment; association; prior locoregional ... See more keywords